Literature DB >> 33602341

Machine learning-aided risk stratification in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Satoshi Nishiwaki1, Isamu Sugiura2, Daisuke Koyama2, Yukiyasu Ozawa3, Masahide Osaki3, Yuichi Ishikawa4, Hitoshi Kiyoi4.   

Abstract

We used the eXtreme Gradient Boosting algorithm, an optimized gradient boosting machine learning library, and established a model to predict events in Philadelphia chromosome-positive acute lymphoblastic leukemia using a machine learning-aided method. A model was constructed using a training set (80%) and prediction was tested using a test set (20%). According to the feature importance score, BCR-ABL lineage, polymerase chain reaction value, age, and white blood cell count were identified as important features. These features were also confirmed by the permutation feature importance for the prediction using the test set. Both event-free survival and overall survival were clearly stratified according to risk groups categorized using these features: 80 and 100% in low risk (two or less factors), 42 and 47% in intermediate risk (three factors), and 0 and 10% in high risk (four factors) at 4 years. Machine learning-aided analysis was able to identify clinically useful prognostic factors using data from a relatively small number of patients.

Entities:  

Keywords:  Machine learning; Philadelphia chromosome-positive acute lymphoblastic leukemia; Prognostic factor; Survival stratification; eXtreme gradient boosting algorithm

Year:  2021        PMID: 33602341      PMCID: PMC7890949          DOI: 10.1186/s40364-021-00268-x

Source DB:  PubMed          Journal:  Biomark Res        ISSN: 2050-7771


  9 in total

1.  Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT.

Authors:  S Nishiwaki; K Imai; S Mizuta; H Kanamori; K Ohashi; T Fukuda; Y Onishi; S Takahashi; N Uchida; T Eto; H Nakamae; T Yujiri; S Mori; T Nagamura-Inoue; R Suzuki; Y Atsuta; J Tanaka
Journal:  Bone Marrow Transplant       Date:  2015-09-21       Impact factor: 5.483

2.  Minimal residual disease-based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for adult Philadelphia-positive acute lymphoblastic leukemia.

Authors:  Jae-Ho Yoon; Gi June Min; Sung-Soo Park; Young-Woo Jeon; Sung-Eun Lee; Byung-Sik Cho; Ki-Seong Eom; Yoo-Jin Kim; Hee-Je Kim; Chang-Ki Min; Seok-Goo Cho; Dong-Wook Kim; Jong Wook Lee; Seok Lee
Journal:  Cancer       Date:  2018-12-06       Impact factor: 6.860

Review 3.  Should anyone with Philadelphia chromosome-positive ALL who is negative for minimal residual disease receive a hematopoietic stem cell transplant in first remission?

Authors:  Mark R Litzow
Journal:  Best Pract Res Clin Haematol       Date:  2016-10-20       Impact factor: 3.020

4.  Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor.

Authors:  Nicholas J Short; Hagop M Kantarjian; Koji Sasaki; Farhad Ravandi; Heidi Ko; C Cameron Yin; Guillermo Garcia-Manero; Jorge E Cortes; Rebecca Garris; Susan M O'Brien; Keyur Patel; Maria Khouri; Deborah Thomas; Nitin Jain; Tapan M Kadia; Naval G Daver; Christopher B Benton; Ghayas C Issa; Marina Konopleva; Elias Jabbour
Journal:  Am J Hematol       Date:  2017-02-03       Impact factor: 10.047

5.  Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1.

Authors:  H Pfeifer; G Cazzaniga; V H J van der Velden; J M Cayuela; B Schäfer; O Spinelli; S Akiki; S Avigad; I Bendit; K Borg; H Cavé; L Elia; S C Reshmi; G Gerrard; S Hayette; M Hermanson; A Juh; T Jurcek; M C Chillón; C Homburg; G Martinelli; V Kairisto; T Lange; T Lion; M C Mueller; F Pane; L Rai; C Damm-Welk; T Sacha; S Schnittger; T Touloumenidou; H Valerhaugen; P Vandenberghe; J Zuna; H Serve; E Herrmann; S Markovic; J J M van Dongen; O G Ottmann
Journal:  Leukemia       Date:  2019-03-11       Impact factor: 11.528

6.  Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.

Authors:  Farhad Ravandi; Jeffrey L Jorgensen; Deborah A Thomas; Susan O'Brien; Rebecca Garris; Stefan Faderl; Xuelin Huang; Sijin Wen; Jan A Burger; Alessandra Ferrajoli; Partow Kebriaei; Richard E Champlin; Zeev Estrov; Pramoda Challagundla; Sa A Wang; Rajyalakshmi Luthra; Jorge E Cortes; Hagop M Kantarjian
Journal:  Blood       Date:  2013-07-08       Impact factor: 22.113

7.  Curing Ph+ ALL: assessing the relative contributions of chemotherapy, TKIs, and allogeneic stem cell transplant.

Authors:  Adele K Fielding
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

8.  Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  J-H Yoon; H-Y Yhim; J-Y Kwak; J-S Ahn; D-H Yang; J-J Lee; S-J Kim; J-S Kim; S J Park; C W Choi; H-S Eom; S-K Park; S-Y Choi; S-H Kim; D-W Kim; S Lee
Journal:  Ann Oncol       Date:  2016-03-06       Impact factor: 32.976

9.  Multi-Lineage BCR-ABL Expression in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Is Associated With Improved Prognosis but No Specific Molecular Features.

Authors:  Satoshi Nishiwaki; Jeong Hui Kim; Masafumi Ito; Matsuyoshi Maeda; Yusuke Okuno; Daisuke Koyama; Yukiyasu Ozawa; Masaharu Gunji; Masahide Osaki; Kunio Kitamura; Yoko Ushijima; Yuichi Ishikawa; Koichi Miyamura; Isamu Sugiura; Hitoshi Kiyoi
Journal:  Front Oncol       Date:  2020-10-23       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.